Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

http://scihub22266oqcxt.onion/ 32400380!ä!32400380 Warning: Undefined variable $yww in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 538 Warning: Undefined variable $yww in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 538       Ugeskr+Laeger 2020 ; 182 (20): ä Nephropedia Template TP {{tp|p=32400380|t=2020. Lack of clinical evidence for the use of hydroxychloroquine to treat SARS-CoV-2 infection |pdf=|usr=}}{{32400380}} gab.com Text Lack of clinical evidence for the use of hydroxychloroquine to treat SARS-CoV-2 infection JO: Ugeskr Laeger http://www.kidney.de/pget.php?&tw=1&pmid=32400380 #FOAvip The severity of COVID-19 disease has led to an urgent need for the discovery of new treatments. Thus, global stocks of hydroxychloroquine (HCQ) have been put under pressure with a study of 26 patients treated with HCQ during their infection with SARS-CoV-2. Despite the study's lack of quality, several countries' medicines agencies subsequently issued guidelines for the use of HCQ for COVID-19. This review aims to elucidate potential mechanisms, which make HCQ treatment interesting in the fight against SARS-CoV-2 infection, as well as the current evidence for clinical use of HCQ to treat COVID-19. Twit Text FOAVip Lack of clinical evidence for the use of hydroxychloroquine to treat SARS-CoV-2 infection ????Ugeskr Laeger http://www.kidney.de/pget.php?&tw=1&pmid=32400380 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32400380 #FOAvip English Wikipedia <ref>{{Cite pmid|32400380}}</ref> Lack of clinical evidence for the use of hydroxychloroquine to treat SARS-CoV-2 infection #MMPMID32400380 Troldborg A; Bartels LE; Deleuran B Ugeskr Laeger 2020[May]; 182 (20): ä PMID32400380show ga The severity of COVID-19 disease has led to an urgent need for the discovery of new treatments. Thus, global stocks of hydroxychloroquine (HCQ) have been put under pressure with a study of 26 patients treated with HCQ during their infection with SARS-CoV-2. Despite the study's lack of quality, several countries' medicines agencies subsequently issued guidelines for the use of HCQ for COVID-19. This review aims to elucidate potential mechanisms, which make HCQ treatment interesting in the fight against SARS-CoV-2 infection, as well as the current evidence for clinical use of HCQ to treat COVID-19. |*Antiviral Agents/pharmacology/therapeutic use[MESH] |*Coronavirus Infections/drug therapy[MESH] |*Hydroxychloroquine/pharmacology/therapeutic use[MESH] |*Pandemics[MESH] |*Pneumonia, Viral/drug therapy[MESH] |Betacoronavirus[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Humans[MESH] Lack of clinical evidence for the use of hydroxychloroquine to treat (epmc).pdf DeepDyve Pubget Overpricing